KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Change in Receivables (2018 - 2025)

Adaptive Biotechnologies' Change in Receivables history spans 8 years, with the latest figure at $5.5 million for Q4 2025.

  • For Q4 2025, Change in Receivables rose 516.69% year-over-year to $5.5 million; the TTM value through Dec 2025 reached $8.6 million, up 130.93%, while the annual FY2025 figure was $8.6 million, 130.93% up from the prior year.
  • Change in Receivables for Q4 2025 was $5.5 million at Adaptive Biotechnologies, up from $536000.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $13.5 million in Q4 2022 and bottomed at -$9.1 million in Q1 2023.
  • The 5-year median for Change in Receivables is $1.5 million (2022), against an average of $2.0 million.
  • The largest annual shift saw Change in Receivables surged 4606.97% in 2022 before it tumbled 1132.37% in 2024.
  • A 5-year view of Change in Receivables shows it stood at $287000.0 in 2021, then soared by 4606.97% to $13.5 million in 2022, then tumbled by 49.91% to $6.8 million in 2023, then crashed by 86.71% to $899000.0 in 2024, then surged by 516.69% to $5.5 million in 2025.
  • Per Business Quant, the three most recent readings for ADPT's Change in Receivables are $5.5 million (Q4 2025), $536000.0 (Q3 2025), and $702000.0 (Q2 2025).